Evercore ISI added TransMedics (TMDX) to the firm’s “Tactical Underperform” list, telling investors that flight tracking suggests Q3 revenue could miss expecations by a few percent. The firm also sees industry reforms leading to potential near-term volatility. Evercore has an Outperform rating and $155 price target on TransMedics shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group Acquires Aircraft for Organ Transport
- TransMedics Group: Strong Long-Term Investment Despite Short-Term Sales Fluctuations
- TransMedics, Mercedes-Benz partner on organ transportation across Italy
- Hold Rating for TransMedics Group Amid Uncertain Transplant Volume and Sales Projections
- TransMedics teams with Mercedes-Benz Group on organ transportation across Italy